Literature DB >> 30185420

Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma.

Ju Youn Lee1, Michail Schizas2, Felipe C Geyer1, Pier Selenica1, Salvatore Piscuoglio1,3, Rita A Sakr2, Charlotte K Y Ng1,3,4, Jose V Scarpa Carniello2, Russell Towers2, Dilip D Giri1, Victor P de Andrade1, Anastasios D Papanastasiou1, Agnes Viale5, Reuben S Harris6, David B Solit5,7, Britta Weigelt1, Jorge S Reis-Filho8,7, Tari A King9.   

Abstract

PURPOSE: Lobular carcinoma in situ (LCIS) is a preinvasive lesion of the breast. We sought to define its genomic landscape, whether intralesion genetic heterogeneity is present in LCIS, and the clonal relatedness between LCIS and invasive breast cancers.Experimental Design: We reanalyzed whole-exome sequencing (WES) data and performed a targeted amplicon sequencing validation of mutations identified in 43 LCIS and 27 synchronous more clinically advanced lesions from 24 patients [9 ductal carcinomas in situ (DCIS), 13 invasive lobular carcinomas (ILC), and 5 invasive ductal carcinomas (IDC)]. Somatic genetic alterations, mutational signatures, clonal composition, and phylogenetic trees were defined using validated computational methods.
RESULTS: WES of 43 LCIS lesions revealed a genomic profile similar to that previously reported for ILCs, with CDH1 mutations present in 81% of the lesions. Forty-two percent (18/43) of LCIS were found to be clonally related to synchronous DCIS and/or ILCs, with clonal evolutionary patterns indicative of clonal selection and/or parallel/branched progression. Intralesion genetic heterogeneity was higher among LCIS clonally related to DCIS/ILC than in those nonclonally related to DCIS/ILC. A shift from aging to APOBEC-related mutational processes was observed in the progression from LCIS to DCIS and/or ILC in a subset of cases.
CONCLUSIONS: Our findings support the contention that LCIS has a repertoire of somatic genetic alterations similar to that of ILCs, and likely constitutes a nonobligate precursor of breast cancer. Intralesion genetic heterogeneity is observed in LCIS and should be considered in studies aiming to develop biomarkers of progression from LCIS to more advanced lesions. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2018        PMID: 30185420      PMCID: PMC6726436          DOI: 10.1158/1078-0432.CCR-18-1103

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  18 in total

1.  FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.

Authors:  Amaia Arruabarrena-Aristorena; Jesper L V Maag; Srushti Kittane; Yanyan Cai; Wouter R Karthaus; Erik Ladewig; Jane Park; Srinivasaraghavan Kannan; Lorenzo Ferrando; Emiliano Cocco; Sik Y Ho; Daisylyn S Tan; Mirna Sallaku; Fan Wu; Barbara Acevedo; Pier Selenica; Dara S Ross; Matthew Witkin; Charles L Sawyers; Jorge S Reis-Filho; Chandra S Verma; Ralf Jauch; Richard Koche; José Baselga; Pedram Razavi; Eneda Toska; Maurizio Scaltriti
Journal:  Cancer Cell       Date:  2020-09-03       Impact factor: 31.743

Review 2.  Problematic breast tumors reassessed in light of novel molecular data.

Authors:  Fresia Pareja; Britta Weigelt; Jorge S Reis-Filho
Journal:  Mod Pathol       Date:  2020-10-06       Impact factor: 7.842

3.  Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma.

Authors:  Fresia Pareja; David N Brown; Ju Youn Lee; Arnaud Da Cruz Paula; Pier Selenica; Rui Bi; Felipe C Geyer; Andrea Gazzo; Edaise M da Silva; Mahsa Vahdatinia; Anthe A Stylianou; Lorenzo Ferrando; Hannah Y Wen; James B Hicks; Britta Weigelt; Jorge S Reis-Filho
Journal:  Clin Cancer Res       Date:  2020-03-27       Impact factor: 12.531

Review 4.  Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Med Sci (Basel)       Date:  2020-03-23

5.  Genetic analysis of pleomorphic and florid lobular carcinoma in situ variants: frequent ERBB2/ERBB3 alterations and clonal relationship to classic lobular carcinoma in situ and invasive lobular carcinoma.

Authors:  Eliah R Shamir; Yunn-Yi Chen; Gregor Krings
Journal:  Mod Pathol       Date:  2020-01-06       Impact factor: 7.842

6.  Endogenous APOBEC3B overexpression characterizes HPV-positive and HPV-negative oral epithelial dysplasias and head and neck cancers.

Authors:  Prokopios P Argyris; Peter E Wilkinson; Matthew C Jarvis; Kelly R Magliocca; Mihir R Patel; Rachel I Vogel; Rajaram Gopalakrishnan; Ioannis G Koutlas; Reuben S Harris
Journal:  Mod Pathol       Date:  2020-07-06       Impact factor: 7.842

7.  Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution.

Authors:  Subramanian Venkatesan; Mihaela Angelova; Clare Puttick; Haoran Zhai; Deborah R Caswell; Wei-Ting Lu; Michelle Dietzen; Panagiotis Galanos; Konstantinos Evangelou; Roberto Bellelli; Emilia L Lim; Thomas B K Watkins; Andrew Rowan; Vitor H Teixeira; Yue Zhao; Haiquan Chen; Bryan Ngo; Lykourgos-Panagiotis Zalmas; Maise Al Bakir; Sebastijan Hobor; Eva Grönroos; Adam Pennycuick; Ersilia Nigro; Brittany B Campbell; William L Brown; Ayse U Akarca; Teresa Marafioti; Mary Y Wu; Michael Howell; Simon J Boulton; Cosetta Bertoli; Tim R Fenton; Robertus A M de Bruin; Apolinar Maya-Mendoza; Eric Santoni-Rugiu; Robert E Hynds; Vassilis G Gorgoulis; Mariam Jamal-Hanjani; Nicholas McGranahan; Reuben S Harris; Sam M Janes; Jirina Bartkova; Samuel F Bakhoum; Jiri Bartek; Nnennaya Kanu; Charles Swanton
Journal:  Cancer Discov       Date:  2021-05-04       Impact factor: 38.272

8.  Multidisciplinary management of CDH1 germinal mutation and prophylactic management hereditary lobular breast cancer: A case report.

Authors:  Sara Mirandola; Francesca Pellini; Eleonora Granuzzo; Maya Lorenzi; Beatrice Accordini; Maurizio Ulgelmo; Alessandra Invento; Davide Lombardi; Marina Caldana; Giovanni Paolo Pollini
Journal:  Int J Surg Case Rep       Date:  2019-04-05

9.  A Rabbit Monoclonal Antibody against the Antiviral and Cancer Genomic DNA Mutating Enzyme APOBEC3B.

Authors:  William L Brown; Emily K Law; Prokopios P Argyris; Michael A Carpenter; Rena Levin-Klein; Alison N Ranum; Amy M Molan; Colleen L Forster; Brett D Anderson; Lela Lackey; Reuben S Harris
Journal:  Antibodies (Basel)       Date:  2019-09-10

10.  Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B.

Authors:  Chai Yeen Goh; Boon Haow Chua; Pieter A Roelofs; Matthew C Jarvis; Teneale A Stewart; Jennifer L McCann; Rebecca M McDougle; Michael A Carpenter; John Wm Martens; Paul N Span; Dennis Kappei; Reuben S Harris
Journal:  Elife       Date:  2020-09-28       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.